Biomed Lublin Wytwornia Surowic i Szczepionek SA
WSE:BML
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Biomed Lublin Wytwornia Surowic i Szczepionek SA
Gross Profit
Biomed Lublin Wytwornia Surowic i Szczepionek SA
Gross Profit Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Gross Profit | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
B
|
Biomed Lublin Wytwornia Surowic i Szczepionek SA
WSE:BML
|
Gross Profit
zł27.9m
|
CAGR 3-Years
10%
|
CAGR 5-Years
15%
|
CAGR 10-Years
N/A
|
|
|
M
|
Mabion SA
WSE:MAB
|
Gross Profit
-zł26.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
-27%
|
|
|
R
|
Read Gene SA
WSE:RDG
|
Gross Profit
zł14.6m
|
CAGR 3-Years
33%
|
CAGR 5-Years
21%
|
CAGR 10-Years
57%
|
|
|
B
|
Bioton SA
WSE:BIO
|
Gross Profit
zł91.8m
|
CAGR 3-Years
-1%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
-5%
|
|
|
U
|
Urteste SA
WSE:URT
|
Gross Profit
-zł298k
|
CAGR 3-Years
-37%
|
CAGR 5-Years
-58%
|
CAGR 10-Years
N/A
|
|
|
S
|
Synthaverse SA
WSE:SVE
|
Gross Profit
zł33m
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
9%
|
|
Biomed Lublin Wytwornia Surowic i Szczepionek SA
Glance View
Biomed Lublin Wytwornia Surowic i Szczepionek SA engages in the manufacture of pharmaceutical products. The company is headquartered in Lublin, Woj. Lubelskie and currently employs 223 full-time employees. The company went IPO on 2011-07-29.
See Also
What is Biomed Lublin Wytwornia Surowic i Szczepionek SA's Gross Profit?
Gross Profit
27.9m
PLN
Based on the financial report for Dec 31, 2022, Biomed Lublin Wytwornia Surowic i Szczepionek SA's Gross Profit amounts to 27.9m PLN.
What is Biomed Lublin Wytwornia Surowic i Szczepionek SA's Gross Profit growth rate?
Gross Profit CAGR 5Y
15%
Over the last year, the Gross Profit growth was 23%. The average annual Gross Profit growth rates for Biomed Lublin Wytwornia Surowic i Szczepionek SA have been 10% over the past three years , 15% over the past five years .
